The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial ...

Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 ...

Q2 2025 Earnings Call Transcript August 5, 2025 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported ...

Sudden unexpected death in epilepsy (SUDEP) is the most significant complication of epilepsy, with an incidence of 1.2 per ...

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

Ubwonko bw’umuntu, ku kigereranyo rusange, ni gacye cyane bushobora kurenza dogere celicius imwe (1C) ku gipimo umubiri wacu ...

CW Petroleum Corp (OTCQB: CWPE) (the 'Company” or 'CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor ...

Read the latest research on irritable bowel syndrome, IBS.